These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 36297630)

  • 21. Emerging Strategies in Stimuli-Responsive Nanocarriers as the Drug Delivery System for Enhanced Cancer Therapy.
    Saravanakumar K; Hu X; Ali DM; Wang MH
    Curr Pharm Des; 2019; 25(24):2609-2625. PubMed ID: 31603055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomes as biocompatible and smart delivery systems - the current state.
    Dymek M; Sikora E
    Adv Colloid Interface Sci; 2022 Nov; 309():102757. PubMed ID: 36152374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Endogenous and Exogenous Stimuli-Responsive Nanocarriers for Drug Delivery and Therapeutics.
    Hatakeyama H
    Chem Pharm Bull (Tokyo); 2017; 65(7):612-617. PubMed ID: 28674332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates on the use of liposomes for active tumor targeting in cancer therapy.
    Yan W; Leung SS; To KK
    Nanomedicine (Lond); 2020 Feb; 15(3):303-318. PubMed ID: 31802702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acoustically-Activated Liposomal Nanocarriers to Mitigate the Side Effects of Conventional Chemotherapy with a Focus on Emulsion-Liposomes.
    Zafar MN; Abuwatfa WH; Husseini GA
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State of the Art of Stimuli-Responsive Liposomes for Cancer Therapy.
    Heidarli E; Dadashzadeh S; Haeri A
    Iran J Pharm Res; 2017; 16(4):1273-1304. PubMed ID: 29552041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancing liposome technology for innovative strategies against malaria.
    Miatmoko A; Octavia RT; Araki T; Annoura T; Sari R
    Saudi Pharm J; 2024 Jun; 32(6):102085. PubMed ID: 38690211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future directions of liposome- and immunoliposome-based cancer therapeutics.
    Park JW; Benz CC; Martin FJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Redox-responsive tetraphenylethylene-buried crosslinked vesicles for enhanced drug loading and efficient drug delivery monitoring.
    Yu Y; Chen Y; Huang J; Wang L; Gu Z; Zhang S
    J Mater Chem B; 2019 Dec; 7(47):7540-7547. PubMed ID: 31720682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal Drug Delivery and Its Potential Impact on Cancer Research.
    Bhattacharya S; Saindane D; Prajapati BG
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2671-2683. PubMed ID: 35440318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis.
    Das SS; Bharadwaj P; Bilal M; Barani M; Rahdar A; Taboada P; Bungau S; Kyzas GZ
    Polymers (Basel); 2020 Jun; 12(6):. PubMed ID: 32580366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smart Nanocarriers as an Emerging Platform for Cancer Therapy: A Review.
    Kenchegowda M; Rahamathulla M; Hani U; Begum MY; Guruswamy S; Osmani RAM; Gowrav MP; Alshehri S; Ghoneim MM; Alshlowi A; Gowda DV
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional Nanosized Drug Delivery Systems for Cancer Applications.
    Vergallo C; Hafeez MN; Iannotta D; Santos HA; D'Avanzo N; Dini L; Cilurzo F; Fresta M; Di Marzio L; Christian C
    Adv Exp Med Biol; 2021; 1295():3-27. PubMed ID: 33543453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme-responsive smart nanocarriers for targeted chemotherapy: an overview.
    Kapalatiya H; Madav Y; Tambe VS; Wairkar S
    Drug Deliv Transl Res; 2022 Jun; 12(6):1293-1305. PubMed ID: 34251612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes.
    Lee SM; Nguyen ST
    Macromolecules; 2013 Dec; 46(23):9169-9180. PubMed ID: 28804160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment.
    AlSawaftah N; Pitt WG; Husseini GA
    ACS Pharmacol Transl Sci; 2021 Jun; 4(3):1028-1049. PubMed ID: 34151199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery.
    Elkhoury K; Koçak P; Kang A; Arab-Tehrany E; Ellis Ward J; Shin SR
    Pharmaceutics; 2020 Sep; 12(9):. PubMed ID: 32906833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers.
    Yue X; Dai Z
    Adv Colloid Interface Sci; 2014 May; 207():32-42. PubMed ID: 24368133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimuli-responsive nanoscale drug delivery systems for cancer therapy.
    Li L; Yang WW; Xu DG
    J Drug Target; 2019 Apr; 27(4):423-433. PubMed ID: 30173577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aptamer-based liposomes improve specific drug loading and release.
    Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
    J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.